Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

As weight loss market rival Novo Nordisk drew headlines for starting a bidding war over a potential $9bn acquisition of ...

Eli Lilly and Co (LLY) reports a 54% revenue increase and raises guidance amid strong product performance and strategic ...

Eli Lilly And Company ( ($LLY) ) has released its Q3 earnings. Here is a breakdown of the information Eli Lilly And Company presented to its ...

Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...

Recursion, Roche and Genentech unveiled the latest product of their nearly four-year artificial intelligence drug discovery collaboration. GSK ’s Blenrep was approved by the FDA for treatment of ...

BofA raised the firm’s price target on Eli Lilly (LLY) to $950 from $900 and keeps a Buy rating on the shares after the company reported “strong” ...

For the Magnificent 7 group, Q3 earnings are expected to be up 11.5% from the same period last year on 15.4% higher revenues, ...

As of 10 AM Eastern Time, the S&P 500 slipped 0.2%, the Dow Jones Industrial Average was up 0.5%, and the Nasdaq Composite ...

Wall Street eyed a US-China truce agreed by Trump and Xi, cooling hopes for a December rate cut and the next batch of Big ...

Our Bureau, New Delhi Friday, October 31, 2025, 14:15 Hrs [IST] Cipla Ltd has reported a growth of 3.7% in net profit for the quarter ...